Agenus expands adjuvant licence and grants right of first negotiation to GSK
This article was originally published in Scrip
GlaxoSmithKline and Agenus have amended their licence and manufacturing agreement covering Agenus' QS-21 Stimulon adjuvant to include additional rights for its use in GSK Biologicals' adjuvant systems. In addition, Agenus granted GSK the first right to negotiate for the purchase of Agenus or certain of its assets. The first right to negotiate will expire after five years.